Evaluation of the contrast density of iomeprol.
The recently developed monomeric nonionic contrast medium iomeprol was tested in concentrations of 150, 200, 250, 300, 350, and 400 mgI/ml in open multicentre Phase III studies. The clinical testing was performed in a nonselected patient population (n = 4811); a total of 15,850 injections of the contrast medium was used. All the common radiological methods were used in the study, which was performed in over 150 centres. The contrast density was evaluated as good or satisfactory in 99% of the total patient population. Relevant heat and pain sensations occurred rarely; severe heat and pain were reported only 1.25% and 0.3% of the patients, respectively.
Schmiedel
E
E
Department of Clinical Development, Bracco-Byk Gulden GmbH, Konstanz, Germany.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000792:Angiography; D015901:Angiography, Digital Subtraction; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007479:Iopamidol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D011856:Radiographic Image Enhancement; D014567:Urography
D003287:Contrast Media; C057937:iomeprol; D007479:Iopamidol